International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 219-229 www.ijprajournal.com ISSN: 2249-7781

An Overview on Cancer

Menaz Kamruddin Kachhi*[1] and Dr. Kiran B. Dhamak[1]
Department of Quality Assurance, Pravara Rural Education Society's College of Pharmacy for Women's, Chincholi, Nashik, MS,India.

Submitted: 01-01-2022 Accepted: 10-01-2022

ABSTRACT
Presently a day's malignant growth is the most predominant perilous infection which is spreading a result of the way of life we are living. Malignancy is because of uncontrolled development of cell which can be restored whenever analyzed in ahead of schedule phase of life. Therapy of malignant growth relies upon the different inner and outer variables causing disease. Malignant growth is screened by various screening test and various medicines are currently accessible these days such as quality treatment, chemotherapy, medical procedure, radiation treatment, immunotherapy and so on In future up to 2030 around 22.2 million cases are relied upon to be analyzed for malignant growth.

Key-words: cancer, carcinoma, carcinogen, therapy, treatment

I. INTRODUCTION

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.[1-2] These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. While these symptoms may indicate cancer, they can also have other causes. Over 100 types of cancers affect humans. Tobacco use is the cause of about 22% of cancer deaths. Another 10% are due to obesity, poor diet, lack of physical activity or excessive drinking of alcohol.[3-5] Other factors include certain infections, exposure to ionizing radiation, and environmental pollutants. In the developing world, 15% of cancers are due to infections such as Helicobacter pylori, hepatitis B, hepatitis C, human papillomavirus infection, Epstein–Barr virus and human immunodeficiency virus (HIV). These factors act, at least partly, by changing the genes of a cell.[6] Typically, many genetic changes are required before cancer develops.[7] Approximately 5–10% of cancers are due to inherited genetic defects Cancer can be detected by certain signs and symptoms or screening tests. It is then typically further investigated by medical imaging and confirmed by biopsy.[8]

The risk of developing certain cancers can be reduced by not smoking, maintaining a healthy weight, limiting alcohol intake, eating plenty of vegetables, fruits,and wholegrains, vaccination a gainst certain infectious diseases, limiting consumption of processed meat and red meat, and limiting exposure to direct sunlight[9] Early detection through screening is useful for cervical and colorectal cancer. [10] The benefits of screening for breast cancer are controversial. Cancer is often treated with some combination of radiationtherapy,surgery, chemotherapy and targ eted therapy. Pain and symptom management are an important part of care. Palliative care is particularly important in people with advanced disease. The chance of survival depends on the type of cancer and extent of disease at the start of treatment. In children under 15 at diagnosis, the five-year survival rate in the developed world is on average 80%.For cancer in the United States, the average five-year survival rate is 66%.

In 2015, about 90.5 million people had cancer. As of 2019, about 18 million new cases occur annually. Annually, it caused about 8.8 million deaths (15.7% of deaths). The most common types of cancer in males are lung cancer, prostate cancer, colorectal cancer, and stomach cancer.[11] In females, the most common types are breast cancer, colorectal cancer, lung cancer, and cervical cancer. If skin cancer other than melanoma were included in total new cancer cases each year, it would account for around 40% of cases. In children, acute lymphoblastic leukemia and brain tumors are most common, except in Africa, where non-Hodgkin lymphoma occurs more often. In 2012, about 165,000 children under 15 years of age were diagnosed with cancer. The risk of cancer increases significantly with age, and many cancers occur

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 219-229 www.ijprajournal.com ISSN: 2249-7781

more commonly in developed countries. Rates are increasing as more people live to an old age and as lifestyle changes occur in the developing world. The financial costs of cancer were estimated at 1.16 trillion USD per year as of 2010.

Etymology and definitions

The word comes from the ancient Greek καρκίνος, meaning crab and tumor. Greek physicians Hippocrates and Galen, among others, noted the similarity of crabs to some tumors with swollen veins. The word was introduced in English in the modern medical sense around 1600. Cancers comprise a large family of diseases that involve abnormal cell growth with the potential to invade or spread to other parts of the body. They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often form a mass or lump, but may be distributed diffusely.[12]

Signs and symptoms

When cancer begins, it produces no symptoms. Signs and symptoms appear as the mass grows or ulcerates. The findings that result depend on the cancer's type and location. Few symptoms are specific. Many frequently occur in individuals who have other conditions. Cancer can be difficult to diagnose and can be considered a "great imitator."

Local symptoms

Local symptoms may occur due to the mass of the tumor or its ulceration. For example, mass effects from lung cancer can block the bronchus resulting in cough or pneumonia; esophageal cancer can cause narrowing of the esophagus, making it difficult or painful to swallow; and colorectal cancer may lead to narrowing or blockages in the bowel, affecting bowel habits. Masses in breasts or testicles may produce observable lumps. Ulceration can cause bleeding that can lead to symptoms such as coughing up blood (lung cancer), anemia or rectal bleeding (colon cancer), blood in the urine (bladder cancer), or abnormal vaginal bleeding (endometrial or cervical cancer). Although localized pain may occur in advanced cancer, the initial tumor is usually painless. Some cancers can cause a buildup of fluid within the chest or abdomen.

Systemic symptoms

Systemic symptoms may occur due to the body's response to the cancer. This may include fatigue, unintentional weight loss, or skin changes. Some cancers can cause a systemic inflammatory state that leads to ongoing muscle loss and weakness, known as cachexia.

Some types of cancer such as Hodgkin disease, leukemias and cancers of the liver or kidney can cause a persistent fever.[13]

Metastasis

Metastasis is the spread of cancer to other locations in the body. The dispersed tumors are called metastatic tumors, while the original is called the primary tumor. Almost all cancers can metastasize. Most cancer deaths are due to cancer that has metastasized.[14]

Causes

It is not generally possible to prove what caused a particular cancer because the various causes do not have specific fingerprints. For example, if a person who uses tobacco heavily develops lung cancer, then it was probably caused by the tobacco use, but since everyone has a small chance of developing lung cancer as a result of air pollution or radiation, the cancer may have developed for one of those reasons. Excepting the rare transmissions that occur with pregnancies and occasional organ donors, cancer is generally not a transmissible disease, however factors that may have contributed to the development of cancer can be transmissible; such as Oncoviruses like hepatitis B, Epstein-Barr virus and HIV.

Diet and exercise

Diet, physical inactivity and obesity are related to up to 30–35% of cancer deaths. In the United States, excess body weight is associated with the development of many types of cancer and is a factor in 14–20% of cancer deaths. A UK study including data on over 5 million people showed higher body mass index to be related to at least 10 types of cancer and responsible for around 12,000 cases each year in that country. Physical inactivity is believed to contribute to cancer risk, not only through its effect on body weight but also through negative effects on the immune system and endocrine system. More than half of the effect from diet is due to over nutrition (eating too much), rather than from eating too few vegetables or other healthful foods.[15]

Infection

Oncoviruses (viruses that can cause cancer) include human papillomavirus (cervical cancer), Epstein–Barr virus (B-cell lymphoproliferative disease and nasopharyngeal carcinoma), Kaposi's sarcoma herpesvirus (Kaposi's sarcoma and primary effusion lymphomas), hepatitis B and hepatitis C viruses (hepatocellular carcinoma) and human T-

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 219-229 www.ijprajournal.com ISSN: 2249-7781

cell leukemia virus-1 (T-cell leukemias). Bacterial infection may also increase the risk of cancer, as seen in Helicobacter pylori-induced gastric carcinoma. Parasitic infections associated with cancer include Schistosoma haematobium (squamous cell carcinoma of the bladder) and the liver flukes, Opisthorchis viverrini and Clonorchis sinensis (cholangiocarcinoma)[16]

Radiation

Radiation exposure such as ultraviolet radiation and radioactive material is a risk factor for cancer. Many non-melanoma skin cancers are due to ultraviolet radiation, mostly from sunlight. Sources of ionizing radiation include medical imaging and radon gas.

Medical use of ionizing radiation is a small but growing source of radiation-induced cancers. Ionizing radiation may be used to treat other cancers, but this may, in some cases, induce a second form of cancer. It is also used in some kinds of medical imaging.

Heredity

The vast majority of cancers are non-hereditary (sporadic). Hereditary cancers are primarily caused by an inherited genetic defect. Less than 0.3% of the population are carriers of a genetic mutation that has a large effect on cancer risk and these cause less than 3–10% of cancer. Some of these syndromes include: certain inherited mutations in the genes BRCA1 and BRCA2 with a more than 75% risk of breast cancer and ovarian cancer, and hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome), which is present in about 3% of people with colorectal cancer, among others.

Physical agents

Physical trauma resulting in cancer is relatively rare. Claims that breaking bones resulted in bone cancer, for example, have not been proven. Similarly, physical trauma is not accepted as a cause for cervical cancer, breast cancer or brain cancer. One accepted source is frequent, long-term application of hot objects to the body. It is possible that repeated burns on the same part of the body, such as those produced by kanger and kairo heaters (charcoal hand warmers), may produce skin cancer, especially if carcinogenic chemicals are also present. Frequent consumption of scalding hot tea may produce esophageal cancer. Generally, it is believed that cancer arises, or a pre-existing cancer is encouraged, during the process of healing, rather than directly by the trauma. However, repeated injuries to the same tissues might promote excessive cell proliferation, which could then increase the odds of a cancerous mutation.[17]

Hormones

Some hormones play a role in the development of cancer by promoting cell proliferation. Insulin-like growth factors and their binding proteins play a key role in cancer cell proliferation, differentiation and apoptosis, suggesting possible involvement in carcinogenesis.

Autoimmune diseases

There is an association between celiac disease and an increased risk of all cancers. People with untreated celiac disease have a higher risk, but this risk decreases with time after diagnosis and strict treatment, probably due to the adoption of a gluten-free diet, which seems to have a protective role against development of malignancy in people with celiac disease. However, the delay in diagnosis and initiation of a gluten-free diet seems to increase the risk of malignancies.[18]

Pathophysiology

Cancers are caused by a series of mutations. Each mutation alters the behavior of the cell somewhat.

Genetics

Cancer is fundamentally a disease of tissue growth regulation. In order for a normal cell to transform into a cancer cell, the genes that regulate cell growth and differentiation must be altered. The affected genes are divided into two broad categories. Oncogenes are genes that promote cell growth and reproduction. Tumor suppressor genes are genes that inhibit cell division and survival. Malignant transformation can occur through the formation of novel oncogenes, the inappropriate over-expression of normal oncogenes, or by the under-expression or disabling of tumor suppressor genes. Typically, changes in multiple genes are required to transform a normal cell into a cancer cell.

Epigenetics

The central role of DNA damage and epigenetic defects in DNA repair genes in carcinogenesis

The classical view of cancer is a set of diseases that are driven by progressive genetic abnormalities that include mutations in tumor-suppressor genes and oncogenes and chromosomal abnormalities. Later epigenetic alterations' role was identified[19]

Epigenetic alterations are functionally relevant modifications to the genome that do not change the nucleotide sequence. Examples of such

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 219-229 www.ijprajournal.com ISSN: 2249-7781

modifications are changes in DNA methylation (hypermethylation and hypomethylation), histone modification[93] and changes in chromosomal architecture (caused by inappropriate expression of proteins such as HMGA2 or HMGA1) [20] Each of these alterations regulates gene expression without altering the underlying DNA sequence. These changes may remain through cell divisions, last for multiple generations and can be considered to be epimutations (equivalent to mutations).

Epigenetic alterations occur frequently in cancers. As an example, one study listed protein coding genes that were frequently altered in their methylation in association with colon cancer. These included 147 hypermethylated and 27 hypomethylated genes. Of the hypermethylated genes, 10 were hypermethylated in 100% of colon cancers and many others were hypermethylated in more than 50% of colon cancers[21] While epigenetic alterations are found in cancers, the epigenetic alterations in DNA repair genes, causing reduced expression of DNA repair proteins, may be of particular importance. Such alterations are thought to occur early in progression to cancer and to be a likely cause of the genetic instability characteristic of cancers.

Metastasis

Metastasis is the spread of cancer to other locations in the body. The dispersed tumors are called metastatic tumors, while the original is called the primary tumor. Almost all cancers can metastasize. Most cancer deaths are due to cancer that has metastasized.

Diagnosis

Most cancers are initially recognized either because of the appearance of signs or symptoms or through screening. Neither of these leads to a definitive diagnosis, which requires the examination of a tissue sample by a pathologist. People with suspected cancer are investigated with medical tests. These commonly include blood tests, X-rays, (contrast) CT scans and endoscopy.

Classification

Cancers are classified by the type of cell that the tumor cells resemble and is therefore presumed to be the origin of the tumor. These types include:

Carcinoma: Cancers derived from epithelial cells. This group includes many of the most common cancers and include nearly all those in the breast, prostate, lung, pancreas and colon.

Sarcoma: Cancers arising from connective tissue (i.e. bone, cartilage, fat, nerve), each of which develops from cells originating in mesenchymal cells outside the bone marrow.

Lymphoma and leukemia: These two classes arise from hematopoietic (blood-forming) cells that leave the marrow and tend to mature in the lymph nodes and blood, respectively[22]

Germ cell tumor: Cancers derived from pluripotent cells, most often presenting in the testicle or the ovary (seminoma and dysgerminoma, respectively).

Blastoma: Cancers derived from immature "precursor" cells or embryonic tissue. Cancers are usually named using -carcinoma, -sarcoma or -blastoma as a suffix, with the Latin or Greek word for the organ or tissue of origin as the root. For example, cancers of the liver parenchyma arising from malignant epithelial cells is called hepatocarcinoma, while a malignancy arising from primitive liver precursor cells is called a hepatoblastoma and a cancer arising from fat cells is called a liposarcoma. For some common cancers, the English organ name is used. For example, the most common type of breast cancer is called ductal carcinoma of the breast. Here, the adjective ductal refers to the appearance of cancer under the microscope, which suggests that it has originated in the milk ducts.

Benign tumors (which are not cancers) are named using -oma as a suffix with the organ name as the root. For example, a benign tumor of smooth muscle cells is called a leiomyoma (the common name of this frequently occurring benign tumor in the uterus is fibroid). Confusingly, some types of cancer use the -noma suffix, examples including melanoma and seminoma.

Prevention

Cancer prevention is defined as active measures to decrease cancer risk. The vast majority of cancer cases are due to environmental risk factors. Many of these environmental factors are controllable lifestyle choices. Thus, cancer is generally preventable. Between 70% and 90% of common cancers are due to environmental factors and therefore potentially preventable.

Medication

Medications can be used to prevent cancer in a few circumstances [23] In the general population, NSAIDs reduce the risk of colorectal cancer; however, due to cardiovascular and gastrointestinal side effects, they cause overall harm when used for prevention. Aspirin has been

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 219-229 www.ijprajournal.com ISSN: 2249-7781

found to reduce the risk of death from cancer by about 7%.COX-2 inhibitors may decrease the rate of polyp formation in people with familial adenomatous polyposis; however, it is associated with the same adverse effects as NSAIDs. Daily use of tamoxifen or raloxifene reduce the risk of breast cancer in high-risk women. The benefit versus harm for 5-alpha-reductase inhibitor such as finasteride is not clear.

Vaccination

Vaccines have been developed that prevent infection by some carcinogenic viruses. Human papillomavirus vaccine (Gardasil and Cervarix) decrease the risk of developing cervical cancer [24] The hepatitis B vaccine prevents infection with hepatitis B virus and thus decreases the risk of liver cancer [25] The administration of human papillomavirus and hepatitis B vaccinations is recommended where resources allow.

Chemotherapy

Chemotherapy is the treatment of cancer with one or more cytotoxic anti-neoplastic drugs (chemotherapeutic agents) as part of a standardized regimen. The term encompasses a variety of drugs, which are divided into broad categories such as alkylating agents and antimetabolites [26] Traditional chemotherapeutic agents act by killing cells that divide rapidly, a critical property of most cancer cells.

It was found that providing combined cytotoxic drugs is better than a single drug; a process called the combination therapy; which has an advantage in the statistics of survival and response to the tumor and in the progress of the disease. A Cochrane review concluded that combined therapy was more effective to treat metastasized breast cancer. However, generally it is not certain whether combination chemotherapy leads to better health outcomes, when both survival and toxicity are considered [27]

Targeted therapy is a form of chemotherapy that targets specific molecular differences between cancer and normal cells. The first targeted therapies blocked the estrogen receptor molecule, inhibiting the growth of breast cancer. Another common example is the class of Bcr-Abl inhibitors, which are used to treat chronic myelogenous leukemia (CML). Currently, targeted therapies exist for many of the most common cancer types, including bladder cancer, breast cancer, colorectal cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, pancreatic cancer, prostate cancer, skin cancer, and thyroid cancer as well as other cancer types [28]

Radiation

Radiation therapy involves the use of ionizing radiation in an attempt to either cure or improve symptoms. It works by damaging the DNA of cancerous tissue, killing it. To spare normal tissues (such as skin or organs, which radiation must pass through to treat the tumor), shaped radiation beams are aimed from multiple exposure angles to intersect at the tumor, providing a much larger dose there than in the surrounding, healthy tissue. As with chemotherapy, cancers vary in their response to radiation therapy [29]

Surgery

Surgery is the primary method of treatment for most isolated, solid cancers and may play a role in palliation and prolongation of survival. It is typically an important part of definitive diagnosis and staging of tumors, as biopsies are usually required. In localized cancer, surgery typically attempts to remove the entire mass along with, in certain cases, the lymph nodes in the area. For some types of cancer this is sufficient to eliminate the cancer [30]

Palliative care

Palliative care is treatment that attempts to help the patient feel better and may be combined with an attempt to treat the cancer. Palliative care includes action to reduce physical, emotional, spiritual and psycho-social distress. Unlike treatment that is aimed at directly killing cancer cells, the primary goal of palliative care is to improve quality of life.

Immunotherapy

A variety of therapies using immunotherapy, stimulating or helping the immune system to fight cancer, have come into use since 1997. Approaches include antibodies, checkpoint therapy, and adoptive cell transfer [31]

Laser therapy

Laser therapy uses high-intensity light to treat cancer by shrinking or destroying tumors or precancerous growths. Lasers are most commonly used to treat superficial cancers that are on the surface of the body or the lining of internal organs. It is used to treat basal cell skin cancer and the very early stages of others like cervical, penile, vaginal, vulvar, and non-small cell lung cancer.

Alternative medicine

Complementary and alternative cancer treatments are a diverse group of therapies, practices and products that are not part of conventional medicine [32] "Complementary

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 219-229 www.ijprajournal.com ISSN: 2249-7781

medicine" refers to methods and substances used along with conventional medicine, while "alternative medicine" refers to compounds used instead of conventional medicine. Most complementary and alternative medicines for cancer have not been studied or tested using conventional techniques such as clinical trials. Some alternative treatments have been investigated and shown to be ineffective but still continue to be marketed and promoted. Cancer researcher Andrew J. Vickers stated, "The label 'unproven' is inappropriate for such therapies; it is time to assert that many alternative cancer therapies have been 'disproven'."

Survival is worse in the developing world [33-38] partly because the types of cancer that are most common there are harder to treat than those associated with developed countries.

Those who survive cancer develop a second primary cancer at about twice the rate of those never diagnosed. The increased risk is believed to be due to the random chance of developing any cancer, the likelihood of surviving the first cancer, the same risk factors that produced the first cancer, unwanted side effects of treating the first cancer (particularly radiation therapy), and to better compliance with screening. [39]

Predicting short- or long-term survival depends on many factors. The most important are the cancer type and the patient's age and overall health. Those who are frail with other health problems have lower survival rates than otherwise healthy people. Centenarians are unlikely to survive for five years even if treatment is successful. People who report a higher quality of life tend to survive longer. People with lower quality of life may be affected by depression and other complications and/or disease progression that both impairs quality and quantity of life. Additionally, patients with worse prognoses may be depressed or report poorer quality of life because they perceive that their condition is likely to be fatal.[40]

People with cancer have an increased risk of blood clots in their veins which can be life-threatening. The use of blood thinners such as heparin decrease the risk of blood clots but have not been shown to increase survival in people with cancer. People who take blood thinners also have an increased risk of bleeding. Although extremely rare, some forms of cancer, even from an advanced stage, can heal spontaneously. This phenomenon is known as the spontaneous remission.

RECENT DEVELOPMENT OF ANTI-CANCER DRUGS [41-50]

1. Pralsetinib

On December 1, the FDA approved pralsetinib (Gavreto) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy or RET fusion–positive thyroid cancer who require systemic therapy and who are radioactive iodine–refractory. On September 4, pralsetinib was granted accelerated approval for adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test. Both pralsetinib approvals were based on findings from the open-label, multicenter, multicohort ARROW clinical trial (ClinicalTrials.gov identifier NCT03037385).

2. Naxitamab

On November 25, naxitamab (Danyelz) was approved in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy. Approval was based on findings from two single-arm, open-label trials: Study 201 (NCT03363373) and Study 12-230 (NCT01757626).

3. Pembrolizumab

On November 13, accelerated approval was granted to pembrolizumab (Keytruda) in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 (Combined Positive Score ≥ 10), as determined by an FDA-approved test. Approval was based on findings from KEYNOTE-355 (NCT02819518), a multicenter, double-blind, randomized, placebo-controlled trial. On October 14, approval was extended for pembrolizumab for adult patients with relapsed or refractory classical Hodgkin lymphoma (HL) and pediatric patients with refractory classical HL or classical HL that has relapsed after two or more lines of therapy. Approval in this setting was based on findings from KEYNOTE-204 (NCT02684292), a phase III, randomized, open-label trial. On June 29, pembrolizumab was approved for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high or mismatch repair–deficient colorectal cancer. This approval was based on findings from KEYNOTE-

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 219-229 www.ijprajournal.com ISSN: 2249-7781

177 (NCT02563002), a multicenter, international, open-label, active-controlled, randomized trial. On June 24, pembrolizumab was approved for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation. Approval was based on findings from the multicenter, multicohort, nonrandomized, open-label KEYNOTE-629 trial (NCT03284424). On June 16, accelerated approval was granted to pembrolizumab for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high [≥ 10 mutations/megabase] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and no satisfactory alternative treatment options. Approval was based on a multicenter, nonrandomized, open-label trial, KEYNOTE-158 (NCT02628067). On April 28, accelerated approval was granted to a new dosing regimen of 400 mg every 6 weeks for pembrolizumab across all currently approved adult indications, in addition to the current 200 mg every-3-weeks dosing regimen. This approval was based on cohort B of KEYNOTE-555 (NCT03665597), an international, single-arm, multicenter study.

4. Venetoclax

On October 16, approval was granted to venetoclax (Venclexta) in combination with azacitidine, decitabine, or low-dose cytarabine for untreated acute myeloid leukemia (AML). Approval was based on findings from two randomized, double-blind, placebo-controlled trials: VIALE-A (NCT02993523) and VIALE-C (NCT03069352).

5. Nivolumab/Ipilimumab and Nivolumab Alone

On October 2, nivolumab (Opdivo) plus ipilimumab (Yervoy) was approved as first-line treatment for adult patients with unresectable malignant pleural mesothelioma. Approval was based on findings from CheckMate 743 (NCT02899299), a randomized, open-label trial.On June 10, nivolumab monotherapy was approved for patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy. Approval was based on ATTRACTION-3 (NCT02569242), a multicenter, randomized, active-controlled, open-label trial. On May 26, nivolumab plus ipilimumab and two cycles of platinum-doublet chemotherapy was approved as first-line treatment of patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations. Approval in this setting was based on CheckMate 9LA (NCT03215706), a randomized, open-label trial. On May 15, the combination of nivolumab plus ipilimumab was approved as first-line treatment for patients with metastatic NSCLC whose tumors express PD-L1 (≥ 1%), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. This approval was based on CheckMate 227 (NCT02477826), a randomized, open-label, multipart trial. On March 10, accelerated approval was granted to the combination of nivolumab and ipilimumab for patients with hepatocellular carcinoma who have been previously treated with sorafenib. Approval was based on cohort 4 of CheckMate 040 (NCT01658878) a multicenter, multicohort, open-label trial.

6. Azacitidine

On September 1, azacitidine tablets (Onureg) were approved for continued treatment of patients with AML who achieved first complete remission or complete remission with incomplete blood cell count recovery following intensive induction chemotherapy and who are not able to complete intensive curative therapy. This oral form of azacitidine should not be substituted for intravenous or subcutaneous formulations, which have different indications and dosing regimens. Approval was based on findings from QUAZAR (NCT01757535), a multicenter, randomized, double-blind, placebo-controlled trial.

7. Daratumumab Combinations

On August 20, carfilzomib (Kyprolis) and daratumumab (Darzalex) in combination with dexamethasone was approved for adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. Approval was based on findings from -CANDOR (NCT03158688), a randomized, open-label, multicenter trial. On May 1, a fixed combination of daratumumab and hyaluronidase-fihj (Darzalex Faspro) was approved for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. Approval was based on COLUMBA (NCT03277105), an open-label noninferiority trial.

8. Belantamab Mafodotin-blmf

On August 5, belantamab mafodotin-blmf (Blenrep) was approved for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Approval was based on findings from DREAMM-2 (NCT 03525678), an open-label, multicenter trial.

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 1 Jan-Feb 2022, pp: 219-229 www.ijprajournal.com ISSN: 2249-7781

9. Tafasitamab-cxix

On July 31, accelerated approval was granted to tafasitamab-cxix (Monjuvi), a CD19-directed cytolytic antibody, indicated in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplant. Accelerated approval was based on findings from L-MIND (NCT02399085), an open-label, multicenter, single-arm trial.

10. Atezolizumab Combinations and Monotherapy

On July 30, atezolizumab (Tecentriq) was approved in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation–positive unresectable or metastatic melanoma. Approval was based on findings from a double-blind, randomized, placebo-controlled, multicenter trial (IMspire150, NCT02908672). On May 29, atezolizumab in combination with bevacizumab (Avastin) was approved for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. Approval was based on IMbrave150 (NCT03434379), a multicenter, international, open-label, randomized trial.

On May 18, atezolizumab monotherapy was approved for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression or PD-L1–stained tumor-infiltrating immune cells covering at least 10% of the tumor area, with no EGFR or ALK genomic tumor aberrations. Approval was based on IMpower110 (NCT02409342), a multicenter, international, randomized, open-label trial.

11. Brexucabtagene Autoleucel

On July 24, accelerated approval was granted to brexucabtagene autoleucel (Tecartus), a CD19-directed genetically modified autologous T-cell immunotherapy, for adult patients with relapsed or refractory mantle cell lymphoma. Approval was based findings from ZUMA-2 (NCT02601313), an open-label, multicenter, single-arm trial.

II. CONCLUSION

As of late, impressive consideration has been centered on recognizing normally happening substances equipped for hindering, impeding, or then again turning around the course of multistage carcinogenesis. Anticancer medication having low secondary effects, actuating apoptosis and target explicit Cytotoxicity to the malignancy cells is medications of decision.

REFERENCES

[1]. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB (September 2008). "Cancer is a preventable disease that requires major lifestyle changes". Pharmaceutical Research. **25** (9): 2097–116.

[2]. GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. **388** (10053): 1545–1602.

[3]. GBD 2015 Mortality and Causes of Death, Collaborators. (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. **388** (10053): 1459–1544.

[4]. Jayasekara H, MacInnis RJ, Room R, English DR (May 2016). "Long-Term Alcohol Consumption and Breast, Upper Aero-Digestive Tract and Colorectal Cancer Risk: A Systematic Review and Meta-Analysis". Alcohol and Alcoholism. **51** (3): 315–30.

[5]. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T (2012). "American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity". CA: A Cancer Journal for Clinicians Cancer J Clin. **62** (1): 30–67.

[6]. Parkin DM, Boyd L, Walker LC (December 2011). "16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010". British Journal of Cancer. 105 Suppl 2: S77–81.

[7]. Gøtzsche PC, Jørgensen KJ (June 2013). "Screening for breast cancer with mammography". The Cochrane Database of Systematic Reviews. **6** (6): CD001877.

[8]. Sciacovelli, Marco; Schmidt, Christina; Maher, Eamonn R.; Frezza, Christian (2020). "Metabolic Drivers in Hereditary

Cancer Syndromes". Annual Review of Cancer Biology. **4**: 77–97.

[9]. Dubas LE, Ingraffea A (February 2013). "Nonmelanoma skin cancer". Facial Plastic Surgery Clinics of North America. **21** (1): 43–53.

[10]. Cakir BÖ, Adamson P, Cingi C (November 2012). "Epidemiology and economic burden of nonmelanoma skin cancer". Facial Plastic Surgery Clinics of North America. **20**(4): 419–22.

[11]. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (February 2011). "Global cancer statistics". CA: A Cancer Journal for Clinicians. **61** (2): 69–90. doi:10.3322/caac.20107.

[12]. Hanahan D, Weinberg RA (January 2000). "The hallmarks of cancer". Cell. **100** (1): 57–70.

[13]. Hanahan D, Weinberg RA (March 2011). "Hallmarks of cancer: the next generation". Cell. **144** (5): 646–74.

[14]. Anguiano L, Mayer DK, Piven ML, Rosenstein D (July–August 2012). "A literature review of suicide in cancer patients". Cancer Nursing. **35** (4): E14–26.

[15]. O'Dell, edited by Michael D. Stubblefield, Michael W. (2009). Cancer rehabilitation principles and practice. New York: Demos Medical. p. 983. ISBN 978-1-933864-33-4.

[16]. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. (May 2011). "Definition and classification of cancer cachexia: an international consensus". The Lancet. Oncology. **12** (5): 489–95.

[17]. Dimitriadis GK, Angelousi A, Weickert MO, Randeva HS, Kaltsas G, Grossman A (June 2017). "Paraneoplastic endocrine syndromes". Endocrine-Related Cancer. **24** (6): R173–R190.

[18]. Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, Flanders WD, Brawley OW, Gapstur SM, Jemal A (January 2018). "Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States". CA: A Cancer Journal for Clinicians. **68** (1): 31–54.

[19]. Cohen S, Murphy ML, Prather AA (January 2019). "Ten Surprising Facts About Stressful Life Events and Disease Risk". Annual Review of Psychology. **70**: 577–597.

[20]. Heikkilä K, Nyberg ST, Theorell T, Fransson EI, Alfredsson L, Bjorner JB, et al. (February 2013). "Work stress and risk of cancer: meta-analysis of 5700 incident cancer events in 116,000 European men and women". BMJ. **346**: f165.

[21]. Tolar J, Neglia JP (June 2003). "Transplacental and other routes of cancer transmission between individuals". Journal of Pediatric Hematology/Oncology. **25** (6): 430–4.

[22]. Biesalski HK, Bueno de Mesquita B, Chesson A, Chytil F, Grimble R, Hermus RJ, Köhrle J, Lotan R, Norpoth K, Pastorino U, Thurnham D (1998). "European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel". CA: A Cancer Journal for Clinicians. **48** (3): 167–76,

[23]. Kuper H, Boffetta P, Adami HO (September 2002). "Tobacco use and cancer causation: association by tumour type". Journal of Internal Medicine. **252** (3): 206–24.

[24]. Kuper H, Adami HO, Boffetta P (June 2002). "Tobacco use, cancer causation and public health impact". Journal of Internal Medicine. **251** (6): 455–66.

[25]. Sasco AJ, Secretan MB, Straif K (August 2004). "Tobacco smoking and cancer: a brief review of recent epidemiological evidence". Lung Cancer. 45 Suppl 2: S3–9.

[26]. Thun MJ, Jemal A (October 2006). "How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking?". Tobacco Control. **15** (5): 345–47.

[27]. Dubey S, Powell CA (May 2008). "Update in lung cancer 2007". American Journal of Respiratory and Critical Care Medicine. **177** (9): 941–46.

[28]. Schütze M, Boeing H, Pischon T, Rehm J, Kehoe T, Gmel G, Olsen A, Tjønneland AM, Dahm CC, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Benetou V, Zylis D, Kaaks R, Rohrmann S, Palli D, Berrino F, Tumino R, Vineis P, Rodríguez L, Agudo A, Sánchez MJ, Dorronsoro M, Chirlaque MD, Barricarte A, Peeters PH, van Gils CH, Khaw KT, Wareham N, Allen NE, Key TJ, Boffetta P, Slimani N, Jenab M, Romaguera D, Wark PA, Riboli E, Bergmann MM

(April 2011). "Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study". BMJ. **342**: d1584.

[29]. Irigaray P, Newby JA, Clapp R, Hardell L, Howard V, Montagnier L, Epstein S, Belpomme D (December 2007). "Lifestyle-related factors and environmental agents causing cancer: an overview". Biomedicine & Pharmacotherapy. **61**(10): 640–58.

[30]. "WHO calls for prevention of cancer through healthy workplaces" (Press release). World Health Organization. 27 April 2007. Archived from the original on 12 October 2007. Retrieved 13 October 2007.

[31]. Kushi LH, Byers T, Doyle C, Bandera EV, McCullough M, McTiernan A, Gansler T, Andrews KS, Thun MJ (2006). "American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity". CA: A Cancer Journal for Clinicians. **56** (5): 254–81, quiz 313–14.

[32]. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L (August 2014). "Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults". Lancet. **384** (9945): 755–65

[33]. Park S, Bae J, Nam BH, Yoo KY (2008). "Aetiology of cancer in Asia". Asian Pacific Journal of Cancer Prevention. **9** (3): 371–80. ^ Brenner H, Rothenbacher D, Arndt V (2009). "Epidemiology of stomach cancer". Cancer Epidemiology. Methods in Molecular Biology (Clifton, NJ). Methods in Molecular Biology. **472**. pp. 467–77.

[34]. Buell P, Dunn JE (May 1965). "Cancer Mortality Among Japanese Issei and Nisei of California". Cancer. **18** (5): 656–64.

[35]. Pagano JS, Blaser M, Buendia MA, Damania B, Khalili K, Raab-Traub N, Roizman B (December 2004). "Infectious agents and cancer: criteria for a causal relation". Seminars in Cancer Biology. **14** (6): 453–71.

[36]. Ljubojevic S, Skerlev M (2014). "HPV-associated diseases". Clinics in Dermatology. **32** (2): 227–34.

[37]. Samaras V, Rafailidis PI, Mourtzoukou EG, Peppas G, Falagas ME (June 2010). "Chronic bacterial and parasitic infections and cancer: a review". Journal of Infection in Developing Countries. **4** (5): 267–81.

[38]. Brenner DJ, Hall EJ (November 2007). "Computed tomography—an increasing source of radiation exposure". The New England Journal of Medicine. **357** (22): 2277–84.

[39]. Roukos DH (April 2009). "Genome-wide association studies: how predictable is a person's cancer risk?". Expert Review of Anticancer Therapy. **9** (4): 389–92.

[40]. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N (March 2010). "Colorectal cancer". Lancet. **375** (9719): 1030–47Biomarkers & Prevention. **16** (1): 1–3.

[41]. Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI (August 2010). "NCCN Clinical Practice Guidelines Cancer-related fatigue". Journal of the National Comprehensive Cancer Network. **8** (8): 904–31.

[42]. Franklin DJ, Packel L (March 2006). "Cancer-related fatigue". Archives of Physical Medicine and Rehabilitation. **87** (3 Suppl 1): S91–3, quiz S94–5.

[43]. Cramp F, Byron-Daniel J (November 2012). Cramp F (ed.). "Exercise for the management of cancer-related fatigue in adults" (PDF). The Cochrane Database of Systematic Reviews. **11** (9): CD006145.

[44]. Gill P, Grothey A, Loprinzi C (2006). Nausea and Vomiting in the Cancer Patient. Oncology. pp. 1482–1496.

[45]. Chadha V, Shenoi SD (2003). "Hair loss in cancer chemotherapeutic patients". Indian Journal of Dermatology, Venereology and Leprology. **69** (2): 131–2.

[46]. Lemieux J (October 2012). "Reducing chemotherapy-induced alopecia with scalp cooling". Clinical Advances in Hematology & Oncology. **10** (10): 681–2.

[47]. Shapiro J, Price VH (April 1998). "Hair regrowth. Therapeutic agents". Dermatologic Clinics. **16** (2): 341–56.

[48]. Al-Mohanna H, Al-Khenaizan S (2010). "Permanent alopecia following cranial irradiation in a child". Journal of Cutaneous Medicine and Surgery. **14** (3): 141–3.

[49]. Can G, Demir M, Erol O, Aydiner A (June 2013). "A comparison of men and women's experiences of chemotherapy-induced alopecia". European Journal of Oncology Nursing. **17** (3): 255–60.
[50]. Trüeb RM (March 2009). "Chemotherapy-induced alopecia". Seminars in Cutaneous Medicine and Surgery. **28** (1): 11–4.